Lilly To Bring Forward Alzheimer’s Readout
Gamble By Rivals Biogen Is Likely Inspiration
After years of failure, expectations of solanezumab are very low – but Lilly still hoping for a signal.
You may also be interested in...
As Biogen moves to file its controversial amyloid drug aducanumab for approval in the US, two similar investigational Alzheimer's drugs – Eli Lilly's solanezumab and Roche's gantenerumab – did not slow memory loss or cognitive decline in a rare, inherited form of the disease.
With business heavily dependent on sales revenue from Medicare Part D and other US government programs, Lilly will be expected to narrow the gap between US prescription and sales growth.
The FDA has overcome doubts about the drug's safety and reversed its decision in just four months.